Get our monthly newsletter
The European Commission proposal on scientific criteria defining endocrine disruptors (EDCs) is the latest dangerous outgrowth of a highly toxic debate. The chemical lobby, supported by certain Commission factions (notably DG SANTE and the Secretary-General) and some member states (UK and Germany), has put significant obstacles in the way of effective public health and environment regulation.
There are many fundamental flaws in the argumentation they are putting forward. In a guest article, Claire Robinson of GMWatch rebutts many of the claims made by those green activists who have recently “come out” as GMO-proponents.
We pay our taxes, so why don’t corporations? The Big Four are embedded in EU policy-making on tax avoidance and this report concludes that it is time to kick this industry out of EU anti-tax avoidance policy.
Industry lobbyists are spending millions of euros to influence an upcoming EU decision on labelling titanium dioxide – found in everyday products like sunscreen – a “suspected carcinogen”. The lobbying is led by an unregistered trade association and a public relations consultancy; nonetheless, they appear to have the ear of member states and the European Commission.
In her final decision on European Central Bank (ECB) President Mario Draghi’s membership of the Group of Thirty (G30), the European Ombudsman Emily O’Reilly has voiced disappointment about the bank’s reluctance to follow her recommendation to suspend Draghi’s G30 membership and to bar future presidents from joining the group.
Documents released to Corporate Europe Observatory following a Freedom of Information request reveal how pro-biotech lobby platform Public Research Regulation Initiative (PRRI) unites industry, researchers and regulators in ‘like-minded’ groups to influence crucial international biosafety talks under the UN Convention on Biological Diversity (CBD).